ScreenerHero

AKBAAkebia Therapeutics, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · akebia.com
0.9066USD+2.39%Mkt Cap: 251.22M $P/E: —

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypo…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap251.22M $
Enterprise Value298.41M $
Revenue (TTM)219.06M $
Gross Profit196.73M $
Net Income (TTM)-5.34M $
Revenue/Share0.8210 USD
Last Price0.9066 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees194
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS00972D1054
Valuation
P/E (Trailing)—
P/E (Forward)-2.79
PEG—
EV/EBITDA-69.01
EV/Revenue1.36
P/S1.16
P/B9.99
EPS (TTM)-0.12
EPS (Forward)-0.33
52W Range
0.81474% of range3.320
52W High3.320 USD
52W Low0.8147 USD
Profitability
Gross Margin83.29%
Oper. Margin-5.46%
EBITDA Margin-1.97%
Profit Margin-2.26%
ROE-16.39%
ROA-1.42%
Growth
Revenue Growth-21.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF67.99M $
CapEx (TTM)8.10M $
FCF Margin15.35%
FCF Yield13.38%
Net Debt43.64M $
Net Debt/EBITDA-10.09
Balance Sheet
Debt/Equity1.59
Current Ratio1.43
Quick Ratio1.30
Book Value/Sh0.0920 USD
Cash/Share0.5610 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.800 USD
Upside (mean)+319.1%
Target Range1.000 USD – 6.000 USD
$1.000+319.1% to mean$6.000
# Analysts5
Ownership
Shares Out.277.11M
Float270.60M
Insiders4.06%
Institutions43.03%
Short Interest
Short Ratio5.6d
Short % Float7.02%
Short % Out.6.92%
Shares Short19.18M
Short (prev mo.)19.18M
Technical
SMA 501.141 (-20.6%)
SMA 2001.347 (-32.7%)
Beta0.23
S&P 52W Chg18.16%
Avg Vol (30d)4.07M
Avg Vol (10d)6.38M
Technical Indicators
RSI (14)34.8
MACD-0.1001
MACD Signal-0.0748
MACD Hist.-0.0253
BB Upper1.500 USD
BB Middle1.085 USD
BB Lower0.6705 USD
BB Width76.42%
ATR (14)0.0779 USD
Vol Ratio (20d)1.45x